Novartis Kisqali® shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancer
arcticnovartis
Mon, 09/16/2024 – 10:19
Read more about Novartis Kisqali® shows deepening…